Clinical Trial Update: Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial of rituximab in combination with chemotherapy for HIV-associated multicentric Castleman disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Multicentric Castleman Disease

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis | Conditions: HIV Infections, Giant Lymph Node Hyperplasia | Phase 2 | Status: TERMINATED